OBJECTIVES: Utility values used in economic evaluations of new products reflect the strength of preference for the health related quality of life (HRQL) of a given health state. These can be captured using the time trade-off (TTO) methodology. The aim of this study was to elicit societal utility values for states related to chronic lymphocytic leukemia (CLL). METHODS: Nine health states were developed following a literature review, interviews with patients (n=6) and clinicians (n=5), and review by lay members of the public (cognitive debriefing; n=5). These health states were: progression free survival (PFS) on initial intravenous (IV) therapy; PFS on initial oral therapy; PFS on initial therapy with increased hospital visits; PFS without therapy; progression after 1^st line therapy; PFS on 2^nd line therapy; PFS without 2^nd line therapy (post 2^nd line treatment, but not currently receiving therapy); further progression (disease progression after 2 lines of treatment); and relapsed lines of treatment (≥3 lines of treatment). One hundred members of the UK general public valued each health state using the TTO methodology. RESULTS: PFS states were the least burdensome: PFS without therapy (mean utility=0.82); PFS on initial oral therapy (0.71); PFS on initial IV therapy (0.67), apart from PFS on initial therapy with increased hospital visits (0.55). Mean utility for disease progression after 1^st line therapy was 0.66 and for PFS without 2^nd line therapy was 0.71; further progression (0.59), PFS on 2^ndline therapy (0.55), and relapsed lines of treatment (0.42) had greater burdens. CONCLUSIONS: The results show the weights that the general public place on CLL states, underlining the value in maintaining PFS for as long as possible. Findings also highlight the extent to which HRQL declines following first line progression. These findings can support the estimation of quality adjusted life years associated with treatments for CLL.